{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:32:37Z","timestamp":1790058757341,"version":"4.0.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210373","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T18:50:00Z","timestamp":1547664600000},"page":"e0210373","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-782X","authenticated-orcid":true,"given":"Michael","family":"K\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Binner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-7296","authenticated-orcid":true,"given":"Alaeldin","family":"Addas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Dinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Garbade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1007\/s00268-014-2543-x","article-title":"Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy","volume":"38","author":"R Som","year":"2014","journal-title":"World J Surg"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"K Wenke","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients","volume":"29","author":"MR Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"ref4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"JG Robinson","year":"2014","journal-title":"JAMA"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"DJ Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"9965","key":"ref6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"FJ Raal","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"MS Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials","volume":"6","author":"A Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"ref9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"MJ Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"E Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"JG Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"ref12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"CP Cannon","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","article-title":"Post-transplant dyslipidemia: Mechanisms, diagnosis and management","volume":"6","author":"A Agarwal","year":"2016","journal-title":"World J Transplant"},{"issue":"17","key":"ref14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis","volume":"70","author":"A Bayes-Genis","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref15","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors","volume":"133","author":"K Leander","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Z Ding","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages","volume":"30","author":"Z Tang","year":"2012","journal-title":"Int J Mol Med"},{"issue":"258","key":"ref18","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"KR Walley","year":"2014","journal-title":"Sci Transl Med"},{"issue":"20","key":"ref19","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"SJ Bernelot Moens","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V86.2.436.bloodjournal862436","article-title":"Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factor-kappa B in TF induction by diverse agonists","volume":"86","author":"CL Orthner","year":"1995","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","volume":"227","author":"EP Navarese","year":"2017","journal-title":"Int J Cardiol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12265-016-9719-8","article-title":"Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients","volume":"10","author":"V Simha","year":"2017","journal-title":"Journal of cardiovascular translational research"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/ATVBAHA.115.307030","article-title":"Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia","volume":"36","author":"M Kockx","year":"2016","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"issue":"4","key":"ref24","first-page":"336","article-title":"A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus","volume":"18","author":"DO Taylor","year":"1999","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.transproceed.2011.08.074","article-title":"Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen","volume":"43","author":"GA Spinelli","year":"2011","journal-title":"Transplant Proc"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results","volume":"20","author":"BK Kramer","year":"2005","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association\u2014European Renal Association"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.healun.2005.11.452","article-title":"Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients","volume":"25","author":"JA Kobashigawa","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2014.08.003","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report\u20142014; focus theme: retransplantation","volume":"33","author":"LH Lund","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"ref29","article-title":"Incidence and predictors of sudden cardiac death after heart transplantation: A systematic review and meta-analysis","author":"AC Alba","year":"2018","journal-title":"Clin Transplant"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOT.0000000000000370","article-title":"Recent advances in allograft vasculopathy","volume":"22","author":"J Merola","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"issue":"4","key":"ref31","first-page":"319","article-title":"Cardiac allograft vasculopathy: a review","volume":"48","author":"D Ramzy","year":"2005","journal-title":"Can J Surg"},{"issue":"4","key":"ref32","first-page":"420","article-title":"Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation","volume":"16","author":"E Esper","year":"1997","journal-title":"J Heart Lung Transplant"},{"issue":"22","key":"ref33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial","volume":"316","author":"SJ Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"K Wenke","year":"1997","journal-title":"Circulation"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0002-9149(03)00456-9","article-title":"Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction","volume":"92","author":"VY See Jr.","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","article-title":"Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients","volume":"71","author":"R Asleh","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"XL Zhang","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"M Ruscica","year":"2016","journal-title":"Ann Med"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacl.2016.05.004","article-title":"Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report","volume":"10","author":"S Nagashima","year":"2016","journal-title":"J Clin Lipidol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12876-015-0371-6","article-title":"Decreased PCSK9 expression in human hepatocellular carcinoma","volume":"15","author":"M Bhat","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15252\/msb.20177703","article-title":"Network analyses identify liver-specific targets for treating liver diseases","volume":"13","author":"S Lee","year":"2017","journal-title":"Mol Syst Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:44:19Z","timestamp":1588995859000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210373"}},"subtitle":[],"editor":[{"given":"Ying-Mei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210373","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]}}}